Today's guest post is by Pete Salzmann, VP, Immunology at Lilly. 

During my training as a physician at the University of California, San Francisco, I often worked with patients facing conditions that were difficult to diagnose and challenging to treat. At the time – the mid-1990s -- remission was particularly elusive for people with rheumatic diseases such as rheumatoid arthritis (RA).

This year also marks the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference, currently taking place in Boston. The meeting brings together worldwide leaders to discuss new results and issues important to the development of the next generation of treatments for this devastating disease. Spending nearly 30 years in the lab conducting clinical studies, Lilly scientists are among those leaders.